Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
about
Antiviral treatment for preventing postherpetic neuralgiaVaccination for preventing postherpetic neuralgiaAntiviral treatment for preventing postherpetic neuralgiaVaccination for preventing postherpetic neuralgiaAntiviral treatment for preventing postherpetic neuralgiaParsonage-turner syndromeThe topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidenceThe 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its UsePostherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacologyPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysisRecommendations for the Management of Herpes ZosterAcupuncture for the treatment of severe acute pain in herpes zoster: results of a nested, open-label, randomized trial in the VZV Pain Study.Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.Sex differences underlying orofacial varicella zoster associated pain in rats.Varicella-zosterHerpes zoster: diagnostic, therapeutic, and preventive approaches.EFNS guidelines on pharmacological treatment of neuropathic pain.An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy.Postherpetic neuralgia: the never-ending challenge.Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latencyPregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.Communication gaps between physicians and patients with postherpetic neuralgia: results from a national study on practice patterns.Case studies illustrating the management of trigeminal neuropathic pain using topical 5% lidocaine plasters.Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8 % topical patch: a case report.Pregabalin: a new neuromodulator with broad therapeutic indications.Prevention of shingles: safety and efficacy of live zoster vaccine.What is new in neuropathic pain?Pregabalin for pain management.Cervical radiculopathy vs Parsonage-Turner syndrome: a case report.Orofacial pain in cancer: part II--clinical perspectives and management.Diagnosing and managing postherpetic neuralgia.Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia.Complications of varicella zoster virus reactivation.Options for treating postherpetic neuralgia in the medically complicated patient.Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV).Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis.Postherpetic neuralgia #272Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
P2860
Q24200526-3776286E-B671-4A2D-9BE8-5945D9DF1EEFQ24235822-1F568ED7-058A-4E26-A4A9-999EB21CE6F6Q24241326-75072F75-0BE0-45A3-B3BF-B51E43D4F6D9Q24241959-8B70F36F-8722-4BDD-A33A-A4019686FB0DQ24243751-A1379274-4C18-42C9-8EA9-176E8CE5C97AQ24629005-307FAA66-A37E-44F6-9196-49D29978337BQ26765263-0B1810A1-9084-4BE6-AB15-A2BA09BAFC6DQ28069535-8166E0B3-BC54-4593-8087-B155E645FCFDQ28077357-325A1983-3AF6-4BD1-A6F8-4282CAF58300Q28085455-F372833A-482C-4030-A0D2-89319551579AQ28315869-4E59BF55-35C7-49D0-9AB1-A261DA252894Q31016201-83025859-CBD1-42F7-A848-F2BACF1A0641Q31040173-A61766ED-79D1-4D54-B871-A06096B9F076Q33369978-2A148A8A-A37A-4910-A0E2-9C0070EB905EQ33702943-85450343-5279-45CC-BD3C-4009A9B642CAQ33848049-6A8E6ED2-B158-422E-B4F4-8EB30C8BC675Q34376752-65A23D45-0466-4583-83A4-6F8449A1FD4AQ34573607-458E29FA-A56E-4625-9B35-CD167C3BD422Q34590272-60FEE8DD-F87F-4368-99A1-D349A8D33F70Q34592574-F7472F9B-00F7-4D10-A362-7485A9E7B669Q34594761-1CDA6581-3510-406F-AC6C-8868831EFC9EQ34753719-179D537E-76D3-43EB-990A-B2184D5FF542Q35061149-F0306B26-01CC-47BA-A93A-44E0048D55AFQ35666349-13028CA0-7B6D-456A-B4AD-ED75C770CE8CQ36110499-729A74D2-B1CF-4E2F-A263-0BF2AF5699E6Q36240286-3FCAB583-8F66-4CDC-960D-8249F468191DQ36313119-F2DE782D-06BF-4297-A335-68900C9ACE07Q36642986-3FB751C1-45DB-4426-88C8-61C8DD160BF4Q36666506-02C5A9CC-7D27-4BEC-8443-AC6DB30B0260Q36687433-4C474424-B3DC-4460-AA68-9D7732879401Q36823627-3F1D54AD-2B98-434D-BE6E-1706A590C86DQ36831528-165F3B49-9B52-4229-8EDE-CE3827124EC0Q36956756-D50FFB98-502B-47E5-BB5A-95BCE767D549Q36958237-3FD431F0-F3EE-48AE-B862-78FC787784ABQ37119278-8421770D-2178-402F-9F66-B23D11A8886FQ37120711-4BE86574-C85C-41AE-9C14-55EE6351952CQ37136450-7E13225C-FBDF-4ECD-B1C6-9DEC58370397Q37163393-24366505-AD4F-4D84-B34B-509C511B24AFQ37181355-C6BC8B8E-C129-4D8E-93F2-E1E9D74A29DFQ37230366-36CCB3A9-41FC-4818-8D70-E91F46F45AE0
P2860
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Practice parameter: treatment ...... American Academy of Neurology.
@ast
Practice parameter: treatment ...... American Academy of Neurology.
@en
type
label
Practice parameter: treatment ...... American Academy of Neurology.
@ast
Practice parameter: treatment ...... American Academy of Neurology.
@en
prefLabel
Practice parameter: treatment ...... American Academy of Neurology.
@ast
Practice parameter: treatment ...... American Academy of Neurology.
@en
P2093
P1433
P1476
Practice parameter: treatment ...... American Academy of Neurology.
@en
P2093
C Boutwell
Quality Standards Subcommittee of the American Academy of Neurology
R M Dubinsky
Z El-Chami
P304
P356
10.1212/01.WNL.0000140708.62856.72
P407
P577
2004-09-01T00:00:00Z